• Product name
  • Description
    Rabbit polyclonal to Cyclin D1
  • Tested applications
    Suitable for: ELISA, IHC-P, WBmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Synthetic peptide corresponding to Human Cyclin D1.

  • Positive control
    • Jurkat cell extract, treated with EGF (200ng/ml, 30mins), human brain tissue.



Our Abpromise guarantee covers the use of ab61758 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notes
    ELISA: 1/40,000.
    IHC-P: 1/50 - 1/100.
    WB: 1/500 - 1/1000. Detect bands of approximately 31 and 21 kDa (predicted molecular weight: 31 kDa).

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • Function
      Essential for the control of the cell cycle at the G1/S (start) transition.
    • Involvement in disease
      Note=A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.
      Note=A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.
      Defects in CCND1 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.
    • Sequence similarities
      Belongs to the cyclin family. Cyclin D subfamily.
    • Post-translational
      Phosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.
      Ubiquitinated, primarily as 'Lys-48'-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB (By similarity). Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to stabilize it.
    • Cellular localization
    • Information by UniProt
    • Database links
    • Alternative names
      • AI327039 antibody
      • B cell CLL/lymphoma 1 antibody
      • B cell leukemia 1 antibody
      • B cell lymphoma 1 protein antibody
      • B-cell lymphoma 1 protein antibody
      • BCL 1 antibody
      • BCL-1 antibody
      • BCL-1 oncogene antibody
      • BCL1 antibody
      • BCL1 oncogene antibody
      • ccnd1 antibody
      • CCND1/FSTL3 fusion gene, included antibody
      • CCND1/IGHG1 fusion gene, included antibody
      • CCND1/IGLC1 fusion gene, included antibody
      • CCND1/PTH fusion gene, included antibody
      • CCND1_HUMAN antibody
      • cD1 antibody
      • Cyl 1 antibody
      • D11S287E antibody
      • G1/S specific cyclin D1 antibody
      • G1/S-specific cyclin-D1 antibody
      • Parathyroid adenomatosis 1 antibody
      • PRAD1 antibody
      • PRAD1 oncogene antibody
      • U21B31 antibody
      see all


    • Human brain tissue stained with ab61758 at 1/50 dilution, with and without the immunising peptide.
    • All lanes : Anti-Cyclin D1 antibody (ab61758) at 1/500 dilution

      Lane 1 : extract from Jurkat cells, treated with EGF (200ng/ml, 30mins).
      Lane 2 : extract from Jurkat cells, treated with EGF (200ng/ml, 30mins), and the immunising peptide.

      Predicted band size : 31 kDa
      Observed band size : 31 kDa
      Additional bands at : 21 kDa. We are unsure as to the identity of these extra bands.


    This product has been referenced in:
    • Doñate C  et al. Anti-JAM-C therapy eliminates tumor engraftment in a xenograft model of mantle cell lymphoma. J Leukoc Biol 100:843-853 (2016). Read more (PubMed: 27256571) »
    • Jung HJ  et al. Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma. Am J Hematol 87:1057-64 (2012). Human . Read more (PubMed: 22965904) »

    See all 4 Publications for this product

    Customer reviews and Q&As

    Thank you for contacting us.
    If we list an antibody as tested, that means the product has been validated for that application and we will cover it under our Abpromise guarantee. If we don't list an application as tested, it generally means that we...

    Read More


    Sign up